ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Entry into a Material Definitive AgreementItem 1.01Entry into a Material Definitive Agreement
On December 14, 2017, Ultragenyx Pharmaceutical Inc. (the “Company”) and Ultragenyx International UX003 Ltd., a wholly-owned subsidiary of the Company (together with the Company, the “Sellers”), entered into an Asset Purchase Agreement (the “Agreement”) with Novartis Pharma AG to which the Sellers agreed to sell their Rare Pediatric Disease Priority Review Voucher (“PRV”). The PRV was awarded to the Company by the U.S. Food and Drug Administration in connection with the approval of Mepsevii™ (vestronidase alfa-vjbk). In consideration for the PRV, Novartis will pay the Sellers $130,000,000 upon closing of the PRV purchase. Closing of the PRV purchase is subject to customary conditions, including the expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Agreement contains customary representations, warranties and covenants.
The foregoing summary of the Agreement is qualified in its entirety by the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report onForm10-Kfor the year ended December 31, 2017, and incorporated herein by reference.
On December 18, 2017, the Company also issued a press release announcing its entry into the Agreement. A copy of the press release is filed as Exhibit99.1 to this Current Report onForm8-Kand is incorporated by reference into this Item 1.01.
Item 1.01Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description
99.1Press Release, dated December 18, 2017
Ultragenyx Pharmaceutical Inc. ExhibitEX-99.1 2 rare-ex991_6.htm EX-99.1 rare-ex991_6.htm Exhibit 99.1 Contact Ultragenyx Pharmaceutical Inc. Investors & Media Danielle Keatley 415-475-6876 Ultragenyx Sells Priority Review Voucher for $130 million Novato,…To view the full exhibit click here
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
